Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobinâ„¢ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity

GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress